CN105111314B - Novel fusion protein, pharmaceutical composition, preparation method and application thereof - Google Patents

Abstract

Translated fromChinese

本发明公开的是一种新型融合蛋白，以及该新型融合蛋白组成的药物组合物及该新型融合蛋白的制备方法和用途。本发明中该新型融合蛋白的结构通式如下：X‑连接肽‑Y‑连接肽‑IgG Fc片段或Y‑连接肽‑X‑连接肽‑IgG Fc片段；其中，X为VEGF‑Trap及其衍生物；Y为PD‑1抗体片段及其衍生物或者PD‑1拮抗剂片段及其衍生物。本发明具有新生血管抑制和T细胞免疫激活作用，而且还具有两种功能的协同促进的作用，使抑制肿瘤生长的功能更加显著。

The present invention discloses a novel fusion protein, a pharmaceutical composition composed of the novel fusion protein, and a preparation method and use of the novel fusion protein. The general structural formula of the novel fusion protein in the present invention is as follows: X-connecting peptide-Y-connecting peptide-IgG Fc fragment or Y-connecting peptide-X-connecting peptide-IgG Fc fragment; wherein X is VEGF-Trap and its derivatives; Y is PD-1 antibody fragment and its derivatives or PD-1 antagonist fragment and its derivatives. The present invention has the effects of inhibiting new blood vessels and activating T cell immunity, and also has the effect of synergistic promotion of the two functions, making the function of inhibiting tumor growth more significant.

Description

A kind of new fusion protein, pharmaceutical composition and its preparation method and application

The present invention relates to a kind of fusion proteins, and in particular to be it is a kind of inhibit tumour growth new fusion protein and medicineThe preparation method and purposes of compositions and the new fusion protein.

Background technique

Immunologic escape is a very important step in the deterioration process of tumour.Tumour cell is by avoiding human immune systemLethal effect be able to fast-growth, to promote the generation of cancer.T cell surface important negative regulatory molecule PD-1, CTLA-4 and TIM-3 is able to suppress the immunologic cytotoxicity effect of T cell in development of cancer.Currently, clinically have for PD-1 andThe drug of CTLA-4 target spot, these drugs clinically therapeutic effect highly significant.

Programmed cell death 1 (PD-1) receptor is mainly expressed in the T cell of activation and B cell, and major function is suppressionThe activation of immune system cell processed, this is also a kind of normal homeostasis of immune system, because excessive T/B cell-stimulating can drawAutoimmunity disease is played, so PD-1 is one of amulet of our human bodies.In pathological conditions, tumor microenvironment can induce infiltrationT cell height express PD-1 molecule, tumour cell can high expression PD-1 ligand PD-L1 and PD-L2, cause in tumor microenvironmentPD-1 signal path sustained activation, T cell function be suppressed, can not killing tumor cell, so as to cause the generation of cancer.It blocksThe PD-1 antibody of this signal path can partially restore the function of T cell, and T cell is made to can continue to killing tumor cell.At presentFor PD-1 antibody there are two drug list, be Nivolumab and Pembrolizumab respectively, the two is clinically rightKinds cancer shows significant therapeutic effect.

VEGF-A is the generation factor of a kind of angiogenesis promoting of tumor cells expression, its main function is to provide immuneThe microenvironment of inhibition creates favorable conditions for the proliferation and cancer of tumour cell.Scientist Magali Terme(Magali T, Thibault V, et al, 2015, J. Exp. Med.212:139-148) research discovery VEGF-A is builtTumor microenvironment can cause the up-regulation of CD8+T cell surface PD-1 molecule, act on so as to cause the immunologic cytotoxicity of CD8+T cellIt reduces.Find that the stimulation of VEGF-A can cause TIM-3 simultaneously, CTLA-4, LAG-3 etc. inhibit the expression of molecule.

Has the report using VEGF-A antibody and PD-1 antibody URIN Treatment tumour in the prior art, in clinical application oftenIt is often single use one of antibody or is treated simultaneously using two kinds of antibodies on tumor, when simultaneously using above two anti-It then needs daily multiple injection to be administered when body is treated, not only makes troubles to operator, but also also brought more to subjectIt is mostly painful.

Summary of the invention

It is an object of the invention to overcome in the prior art VEGF-Trap and PD-1 antibody need in clinical application dailyThe problem of multiple injection is administered, providing not only has VEGF TRAP and PD-1 antibody physiological activity, but also one kind with long-acting functionNew fusion protein, and disclose the pharmaceutical composition of new fusion protein composition and the preparation method of the new fusion proteinAnd purposes.

In order to achieve the above objectives, technical scheme is as follows:

A kind of novel fusion protein, general structure are as follows:

X- link peptide-Y- link peptide-IgG Fc segment or Y- link peptide-X- link peptide-IgG Fc segment；

Wherein, X is VEGF-Trap and its derivative；Y is PD-1 antibody fragment and its derivative or PD-1 antagonist pieceSection and its derivative.

The present invention is not simply to mix two kinds of antibody proteins, but form one after being merged using two kinds of antibodyThe novel fusion protein of kind, the albumen can inhibit the activity of PD-1 and VEGF-A simultaneously, to can inhibit tumor vascular newIt is raw, but the generation and activity of energy double inhibition PD-1, a plurality of pathway activation T cell；It has can hungry tumour cell andActivate the effect of T cell killing tumor cell.

PD-1 antibody and VEGF-A antibody is applied in combination to PD-1 antibody and VEGF-A antibody is used alone in the present invention, withAnd the effect of the fusion protein VNI combined using PD-1 antibody and VEGF-A antibody is carried out tumour growth situation in mouse and detected,Testing result is as shown in table 7 and Fig. 3.By table 7: using new fusion protein of the invention, be not only only capable of having simultaneouslyThere are two types of the functions of the hungry tumour cell of antibody difference and activation T cell killing tumor cell, and can also reach two kinds of functionThe collaboration facilitation of energy makes to inhibit the function of tumour growth more significant；Also, by shown in Fig. 3, using of the invention newType fusion protein also has the function of effectively extending each antibody units physiological active functions effect.

Preferably, the link peptide is amino acid sequence shown in formula (Gly-Gly-Gly-Gly-Ser) n, which is 1~4Integer.The amino acid sequence of the X is SEQ ID NO:1 or SEQ ID NO:3 or its nucleotide coding sequence is SEQ IDNO:2 or SEQ ID NO:4.The amino acid sequence of the Y is SEQ ID NO:5 or SEQ ID NO:7 or its nucleotide codingSequence is SEQ ID NO:6 or SEQ ID NO:8.The IgG Fc segment is IgG1 Fc segment, IgG2 Fc segment, IgG3Fc segment or IgG4 Fc segment, amino acid sequence are respectively SEQ ID NO:9,11,13,15 or its nucleotide coding sequenceRespectively SEQ ID NO:10,12,14,16.

A method of new fusion protein being prepared, by the coding of any one of the claim 1-6 new fusion proteinNucleotide sequence is inserted into expression vector, and this expression vector is introduced corresponding expression system and then carries out the table of fusion proteinIt reaches.The expression vector of fusion protein of the present invention can be recombinant eukaryon expression vector, preferred mammal cell expression vector；?It can be recombinant virus expression vector, preferably adeno-associated virus or adenovirus vector.

The host cell of fusion protein in above-mentioned expression system can be Chinese hamster ovary celI and its subbreed or 293 cells and its AsiaSystem.

A kind of pharmaceutical composition, by new fusion protein described in any one of claims 1-6 with it is pharmaceutically acceptableCarrier or excipient composition.

Further, the dosage form of described pharmaceutical composition is injection, injection freeze-dried powder.

A kind of purposes of new fusion protein, the new fusion protein described in any one of claims 1-6 is for swellingThe treatment of tumor；The tumour is melanoma, lung cancer, liver cancer, lymthoma, colon cancer, colorectal cancer, breast cancer, oophoroma, uterine neckOne in cancer, gastric cancer, cholangiocarcinoma, gallbladder cancer, the cancer of the esophagus, kidney, glioma, melanoma, cancer of pancreas and prostate cancerKind is a variety of.

Compared with prior art, the present invention have the following advantages that and the utility model has the advantages that

1, fusion protein of the invention can not only have there are two types of the hungry tumour cell of antibody difference simultaneously and activate T thinThe function of born of the same parents' killing tumor cell, and the collaboration facilitation of two kinds of functions can also be reached, make the function of inhibiting tumour growthIt is more significant；

2, new fusion protein of the invention can effectively extend each antibody units physiological active functions effect, and then reduce oneTotal dosage of a course for the treatment of reduces drug cost；

3, the present invention can effectively reduce the number of drug administration by injection, mitigate administration pain.

Detailed description of the invention

Fig. 1 is the EC50 value curve synoptic diagram that VNI influences HUVEC cell Proliferation.

Fig. 2 is the curve synoptic diagram that VNI stimulates PBMC generation IFN γ.

Fig. 3 is the comparative situation schematic diagram that source of mouse VNI inhibits tumour growth in vivo.

Specific embodiment

Below with reference to embodiment, the present invention is described in further detail, embodiments of the present invention are not limited thereto.

The preparation of 1 albumen of embodiment

A kind of new fusion protein, general structure are as follows:

X- link peptide-Y- link peptide-IgG Fc segment；Wherein, X is VEGF-Trap and its derivative；Y is PD-1 antibodySegment and its derivative or PD-1 antagonist segment and its derivative.

The X is VEGF-Trap in the present embodiment, and nucleotide sequence is as shown in SEQ ID NO:4；Y is PD-1 antibody pieceSection, nucleotide sequence is as shown in SEQ ID NO:6；The link peptide is ammonia shown in formula (Gly-Gly-Gly-Gly-Ser) nBase acid sequence, n is 3 in the link peptide；The nucleotide sequence of IgG Fc segment is as shown in SEQ ID NO:16；That is, the present embodimentThe nucleotide sequencing of middle synthesis fusion protein is as shown in SEQ ID NO:18.

The specific synthetic route of above-mentioned new fusion protein is as follows in the present embodiment:

1. construction recombination plasmid

1.1 according to the logical of X- link peptide-Y- link peptide-IgG Fc segment or Y- link peptide-X- link peptide-IgG Fc segmentFormula obtains the genetic fragment and primer of synthesis fusion protein, and the genetic fragment for synthesizing fusion protein and primer is recombinated to matterPuc57-VNI plasmid is obtained in grain carrier puc57.The nucleotide sequencing of the synthesis fusion protein such as SEQ ID NO:Shown in 13, the gene and primer are synthesized by Beijing Jin Weizhi company of specialized company.

Puc57-VNI plasmid and pCHO1.0 plasmid are carried out double digestion processing by 1.2 respectively, the foundation of the digestion system:

Following ingredient: 40 μ l, Buffer4 10 of pCHO1.0 plasmid or puc57-VNI plasmid is added in 1.5ml EP pipeEach 5 μ l of μ l, Avr II and BstZ17I, 45 μ l of aqua sterilisa, reacts 5h at 37 DEG C after mixing, utilizes QIAGEN product purification reagentBox recycling, obtains genetic fragment pCHO1.0 and VNI respectively.

1.3 under the action of T4 ligase, will be with the genetic fragment pCHO1.0 and VNI for recycling acquisition after identical digestionGenetic fragment connection；Coupled reaction system is as follows:

It is added the pCHO1.0 of following 2 μ l of ingredient in 1.5ml EP pipe, the VNI of 6 μ l, 10 × T4 Buffer 1 μ l, 1The T4 DNA ligase of μ l, reacts 4h or more under room temperature (20 DEG C or so) after mixing, connection product is converted to Top10 large intestine barIn bacterium competence cell, it is coated on 2YT (KANA) plating medium and stands overnight for 37 DEG C, plate number pCHO1.0-VNI.

1.4 from the several recombination single colonies of picking each in pCHO1.0-VNI plate after culture as pcr template, respectivelyCarry out PCR screening and identification；

Bacterium solution pcr amplification reaction system (20 μ L of total volume): 2 × Taq HS, 10 μ L, 2 μ L of bacterium solution template, upstream and downstream are drawnEach 1 μ L of object P1 and P2 (0.3 μm of ol/L of final concentration), is finally mended with distilled water to 20 μ L；Reaction condition: 95 DEG C of 2min, one is followedRing；94 DEG C of 60s, 53 DEG C of 60s, 72 DEG C of 120s, 30 circulations；Last 72 DEG C of 5min.It is analyzed by agarose gel electrophoresisAs a result, selecting the correct bacterium colony with target product.

1.5 carry out digestion identification by extracting after the colony inoculation of PCR screening and identification respectively again；Recombinant bacterium is carried out firstPlasmid extract, then carry out restriction analysis；

Digestion system: it is added following ingredient in 1.5ml EP pipe: plasmid 2 μ l, Buffer1 1 μ l, BSA 0.1 μ l, AvrEach 1 μ l of II and BstZ17I mends aqua sterilisa to 10 μ l, reacts 4h at 37 DEG C after mixing.It is analyzed and is tied by agarose gel electrophoresisFruit selects digestion and identifies correct bacterium colony.

1.6 will identify that correct bacterium colony is inoculated with several bacterium colonies at random and carries out sequencing identification again by bacterium colony PCR and digestion, selectExpression plasmid is taken out to save backup.

2. plasmid transfection and cell screening

Using host cell CHO-S or DG44, plasmid is carried out respectively according to Freedom CHO-S Kit kit specificationTransfection, the cell for being transferred to plasmid are respectively placed in shaking flask culture 8h, the condition of shaking flask culture are as follows: 37 DEG C, 8%CO₂、110rpm/min。Cell viability and cell number are detected by cell counter.

Two steps pressurization screening: the μ g/mL of 10P/100M, 20P/200M(P=10 Puromycin, M=nM is carried out after transfection 48hMTX)；30P/500M, 50P/1000M obtain initial screening cell.Monoclonal cell screening is carried out with limiting dilution assay, passes through detectionExpressing quantity and purity are therefrom preferably cloned expands culture step by step.

3. Protein expression and purification

Screening High producing clones cell, which expands from 96 orifice plates to 24 orifice plates, to be grown, and is then expanded to 6 orifice plates and is grown, expands later to 50mLShake flask grown.

7 days cell culture supernatants of culture are collected, cell fragment is centrifuged off, supernatant is adjusted with 0.45 μm of membrane filtrationPH to 7.4 is saved, with Protein A sepharose affinity column chromatography (HiTrap Protein-A Sepharose affinityColumn the deionized water of) purified fusion albumen, 5 times of bed volumes rinses pillar, then the PBS buffer solution with 5 times of bed volumes(20mM phosphate, pH 7.4) balances pillar, and loading collects efflux detection, with 10 times of volume PBS buffer solution (0.02Mol/L phosphate, pH 7.4) washing removes foreigh protein removing, then using 0.1M glycine buffer (pH3) by destination protein from columnUpper elution, new fusion protein VNI as of the invention.It is detected by SDS-PAGE, the purity of new fusion protein VNI reachesTo 90% or more.

The analysis of embodiment 2.VNI binding kinetics

(1) the binding kinetics analysis of VNI and VEGF-A

25 μ g/ml Biotin-hVEGF-A are incorporated on SA sensor by Loading；It is arranged according to preliminary experiment denseIt spends range: being respectively 10000,5000,1000,500,100nM, using Sample Diluent buffer as blank control.InDynamic analysis in Octet QK detection platform carries out the kinetic parameter of hVEGF-A and VNI, VEGF-Trap and PD1 antibodyDetection, test procedure setting are as shown in table 1:

Table 1

Detect step number	Solution	Step type	Detection time (s)
				1	Sample Diluent buffer	Baseline	120
2	Biotin-hVEGF-A	Loading	360
				3	Sample Diluent buffer	Baseline	120
4	Sample	Association	720
				5	Sample Diluent buffer	Dissociation	1800

The experimental result detected by above-mentioned test procedure is as shown in table 2:

2 binding kinetics parameter of table compares

KD (M)

kon(1/Ms)

kon Error

kdis(1/s)

kdis Error

Full R^2

VNI

1.33E-10

4.34E+05

1.73E+04

5.79E-05

1.70E-05

0.99448

VEGF-Trap

0.83E-10

9.51E+05

6.11E+04

7.93E-05

3.23E-05

0.99368

PD-1 antibody

4.36E-03

1.20E+01

1.25E+01

5.25E-02

1.13E-03

0.91908

Table 2 as above shows that VNI still keeps the high-affinity with VEGF-A, remains to combine VEGF-A well in vitro；ButBinding force is weaker than VEGF-TRAP.And PD-1 antibody and VEGF-A are almost without combination.

(2) the binding kinetics analysis of VNI and PD-1

25 μ g/ml Biotin-h PD-1 are incorporated on SA sensor by Loading；It is arranged according to preliminary experiment denseIt spends range: being respectively 10000,5000,1000,500,100nM, using Sample Diluent buffer as blank control.InDynamic analysis in Octet QK detection platform carries out the kinetic parameter of h PD-1 and VNI, VEGF-Trap and PD1 antibodyDetection, test procedure setting are as shown in table 3:

Table 3

Detect step number	Solution	Step type	Detection time (s)
				1	Sample Diluent buffer	Baseline	120
2	Biotin-hPD-1	Loading	360
				3	SampleDiluent buffer	Baseline	120
4	Sample	Association	720
				5	Sample Diluent buffer	Dissociation	1800

The experimental result detected by above-mentioned test procedure is as shown in table 4:

4 binding kinetics parameter of table compares

KD (M)

kon(1/Ms)

kon Error

kdis(1/s)

kdis Error

Full R^2

VNI

5.5E-10

1.32E+05

7.74E+04

7.32E-05

2.37E-05

0.99646

VEGF-Trap

6.24E-3

3.07E+01

3.29E+02

1.92E-01

1.79E-06

0.89421

PD1 antibody

2.17E-10

9.71E+05

1.19E+03

2.11E-04

1.80E-06

0.99911

Table 4 as above shows that VNI is in conjunction with PD-1 holding high-affinity, but binding force is weaker than PD-1 antibody.And PD-1 antibodySegment or antagonist and PD-1 binding force are very weak.

In conclusion VNI is still able to maintain and VEGF-A and PD-1 high affine combination in vitro, thus it is speculated that the molecule has active isomerInterior activity.

The In vitro biological activity of 3. VNI of embodiment detects.

(1) the influence comparative studies to HUVEC cell Proliferation

The HUVEC cell inoculation of logarithmic growth phase is in 96 well culture plates, and 3 × 10³The hole cells/, 100 holes μ l/, 37 DEG C,5%CO₂Cultivate 20h；With Base culture medium prepare different molar concentrations VNI, PD-1 antibody and VEGF-Trap(9.7~It 10000ng/ml) is mixed respectively with the VEGF of 40ng/ml, 37 DEG C of incubation 2h；It is inoculated with 96 orifice plates of HUVEC cell in additionOn, 100 holes μ l/, every group of 3 multiple holes, 37 DEG C, 5%CO₂Continue to be incubated for 96h, negative control group bonus point does not add Base culture medium and completeFull culture medium；Add CCK-8 reagent, 20 μ l/well, 37 DEG C are protected from light incubation 2h, and 450nm detects light absorption value, and VNI is to HUVEC cellThe EC50 value curve synoptic diagram of proliferative effect is as shown in Figure 1, experimental result is as shown in table 5.

Table 5

sample	EC50 (ng/ml)	standard Error	R-Square
				VNI	229.74	20.19	0.983
VEGF-Trap	197.62	17.59	0.979
				PD1 antibody	1.23E12	7.11E15	0.608

It is shown by table 5 and Fig. 1, the In vitro biological activity of VNI is slightly below VEGF-Trap, and PD-1 antibody pairVEGF stimulates HUVEC cell-proliferation activity substantially without inhibiting effect.

(2) to the influence of the cytokine secretion of cytomegalovirus lysate stimulation PBMC cell

From the donor separating peripheral blood mononuclear cells (PBMC) of CMV positive (once infecting cytomegalovirus), CMV is splitSolution object can stimulate this kind of cell to generate IFN γ, and anti-PD-1 antibody can enhance CMV lysate stimulation PBMC and generate IFN γ.

105 people PMBC from CMV positive donor are cultivated in 200 μ l of total volume, and are added in each holeCMV lysate.Anti- PD-1 antibody, VNI and PD-1 antibody fragment or the antagonist of various concentration are added in each hole.OftenRule take 100 μ l culture mediums to measure for cell factor IFN γ after CMC model cell the 4th day from every part of culture, VNI thornSwash PBMC and generates the curve synoptic diagram of IFN γ as shown in Fig. 2, measurement result is as shown in table 6.

Table 6

sample	EC50 (ng/ml)	standard Error	R-Square
				VNI	112.42	16.75	0.951
VEGF-Trap	--	--	--
				PD1 antibody	82.95	15.82	0.978

It is shown by Fig. 2 and table 6, under the effect of CMV lysate, VNI generates IFN in concentration dependant stimulation PBMC cellγ, in low concentration, its ability to function is lower than PD-1 antibody, but suitable with PD-1 antibody effect at high concentrations.VEGF-TRAPPBMC cannot be stimulated to generate IFN γ substantially.

4. source of mouse VNI of embodiment inhibits Growth of Tumors Transplanted Effect study in Mice Body

Since mouse PD-1 and humanization source of people PD-1 antibody do not have cross action, and then source of people PD-1 antibody is caused to existPD-1 can not be blocked to act in Mice Body, PD-1 antibody inhibiting tumor growth, thus this hair cannot be played in Mice BodyIt is bright to use the internal influence that processing is implanted with the mouse of cancerous tumour to examine antibodies on tumor to grow in source of mouse VNI body.

The preparation of source of mouse PD-1 antibody and source of mouse VNI: first use mouse PD-1 immune rat, referring to " tissue cultures and pointDaughter cell technology " (E Zheng chief editor) hybridoma preparation method, anti-mouse PD-1 antibody gene is obtained, by the genetic recombinationInto carrier for expression of eukaryon, source of mouse PD-1 antibody is obtained, the antibody is spare as compareing；Then, egg will be separately merged in the present inventionThe anti-PD-1 antibody fab sequence of the source of people of white VNI is substituted for the fab sequence of mouse PD-1 antibody gene, and it is anti-to form anti-mouse PD-1The fusion protein source of mouse VNI of body and VEGF-TRAP, which is recombinated into carrier for expression of eukaryon, through transfection, expression and purifyingObtain recombination source of mouse VNI.

The female AJ mouse between 6-8 week old is randomly divided into 6 groups according to weight, every group includes 10 animals.At the 0th day2 × 106 SA1/N fibrosarcoma cells for being dissolved in 200 μ l DMEM culture mediums are subcutaneously implanted mouse on right side.With PBS pairsAccording to or 10mg/kg drug-treated mouse.Led at the 1st, 4,8 and 11 day with the about 200 μ l PBS for containing drug or controlIntraperitoneal injection is crossed to be administered to animal dosage.Each group composition is as follows: (1) PBS control group, (2) source of mouse VNI group, (3) source of mouse PD-1 antibody group, (4) VEGF-TRAP group.Tumour growth is monitored to mouse twice a week, continues about 8 weeks.Use electronic caliperThree-dimensional measurement (height × width × length) is carried out to tumour and calculates gross tumor volume.When tumour reaches tumour terminal(1500mm3) or display put to death mouse when being greater than 15% weight loss, account for percentage such as table without tumor mouse after drug-treatedShown in 7, source of mouse VNI inhibits the phenomenon that tumour growth is as shown in Figure 3 in vivo.

Table 7

Group	Study mouse number of elements	Without tumour number of elements (only)	Without tumour percentage (%)
				PBS group	10	0	0
Source of mouse VNI group	10	7	70
				Source of mouse PD-1 antibody group	10	3	30
VEGF-TRAP group	10	0	0

In above-mentioned comparative experiments, 9 mouse about reached tumour terminal at 28 days in PBS group, had 1 mouse tumour to fester；Source of mouse3 mouse of VNI group reached tumour terminal at 56 days, remaining 7 without tumour；7 mouse of source of mouse PD-1 antibody group reached tumour at 56 daysTerminal, remaining 3 mouse is without tumour；VEGF-TRAP group has 6 mouse to reach tumour terminal at 42 days, remaining 4 mouse reached at 49 daysTumour terminal.

By Fig. 3, table 7 and above-mentioned experimental result describe: new fusion protein VNI of the invention, not onlyCan have there are two types of the hungry tumour cell of antibody difference and activate the function of T cell killing tumor cell simultaneously, and can also reachTo the collaboration facilitation of two kinds of functions, make to inhibit the function of tumour growth more significant；Also, pass through shown in Fig. 3, using thisThe new fusion protein of invention also has the function of effectively extending each antibody units physiological active functions effect.

Embodiment 5

The nucleotide serialization of X arranges, the nucleosides of the present embodiment described in X different with the nucleotide serialization of Y column in the present embodimentCoding sequences are SEQ ID NO:4, and the nucleotide coding sequence of the Y is SEQ ID NO:8.The IgG Fc segment isIgG3 Fc segment, the IgG3 Fc segment nucleotide coding sequence are SEQ ID NO:14.

Embodiment 6

The present embodiment the difference from embodiment 1 is that: the segment of IgG Fc described in the present embodiment be IgG2 Fc segment, shouldIgG2 Fc segment nucleotide coding sequence is SEQ ID NO:12.

Above-described embodiment is merely a preferred embodiment of the present invention, and it is not intended to limit the protection scope of the present invention, as long as usingDesign principle of the invention, and the non-creative variation worked and made is carried out on this basis, it should belong to of the inventionWithin protection scope.

SEQUENCE LISTING

<110>Chengdu all generations wins Bioisystech Co., Ltd

<120>a kind of new fusion protein, pharmaceutical composition and its preparation method and application

<130> 2015

<160> 18

<170> PatentIn version 3.3

<210> 1

<211> 205

<212> PRT

<213>unknown

<400> 1

Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu

1 5 10 15

Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val

20 25 30

Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr

35 40 45

Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe

50 55 60

Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu

65 70 75 80

Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg

85 90 95

Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile

100 105 110

Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr

115 120 125

Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys

130 135 140

His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly

145 150 155 160

Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr

165 170 175

Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met

180 185 190

Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys

195 200 205

<210> 2

<211> 615

<212> DNA

<213>artificial sequence

<400> 2

tccgacaccg gtagaccttt cgtagagatg tacagtgaaa tccccgaaat tatacacatg 60

actgaaggaa gggagctcgt cattccctgc cgggttacgt cacctaacat cactgttact 120

ttaaaaaagt ttccacttga cactttgatc cctgatggaa aacgcataat ctgggacagt 180

agaaagggct tcatcatatc aaatgcaacg tacaaagaaa tagggcttct gacctgtgaa 240

gcaacagtca atgggcattt gtataagaca aactatctca cacatcgaca aaccaataca 300

atcatagatg tggttctgag tccgtctcat ggaattgaac tatctgttgg agaaaagctt 360

gtcttaaatt gtacagcaag aactgaacta aatgtgggga ttgacttcaa ctgggaatac 420

ccttcttcga agcatcagca taagaaactt gtaaaccgag acctaaaaac ccagtctggg 480

agtgagatga agaaattttt gagcacctta actatagatg gtgtaacccg gagtgaccaa 540

ggattgtaca cctgtgcagc atccagtggg ctgatgacca agaagaacag cacatttgtc 600

agggtccatg aaaag 615

<210> 3

<211> 202

<212> PRT

<213>unknown

<400> 3

Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His

1 5 10 15

Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro

20 25 30

Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro

35 40 45

Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser

50 55 60

Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val

65 70 75 80

Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn

85 90 95

Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser

100 105 110

Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn

115 120 125

Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His

130 135 140

Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met

145 150 155 160

Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp

165 170 175

Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys

180 185 190

Asn Ser Thr Phe Val Arg Val His Glu Lys

195 200

<210> 4

<211> 615

<212> DNA

<213>artificial sequence

<400> 4

ggtagacctt tcgtagagat gtacagtgaa atccccgaaa ttatacacat gactgaagga 60

agggagctcg tcattccctg ccgggttacg tcacctaaca tcactgttac tttaaaaaag 120

tttccacttg acactttgat ccctgatgga aaacgcataa tctgggacag tagaaagggc 180

ttcatcatat caaatgcaac gtacaaagaa atagggcttc tgacctgtga agcaacagtc 240

aatgggcatt tgtataagac aaactatctc acacatcgac aaaccaatac aatcatagat 300

gtggttctga gtccgtctca tggaattgaa ctatctgttg gagaaaagct tgtcttaaat 360

tgtacagcaa gaactgaact aaatgtgggg attgacttca actgggaata cccttcttcg 420

aagcatcagc ataagaaact tgtaaaccga gacctaaaaa cccagtctgg gagtgagatg 480

aagaaatttt tgagcacctt aactatagat ggtgtaaccc ggagtgacca aggattgtac 540

acctgtgcag catccagtgg gctgatgacc aagaagaaca gcacatttgt cagggtccat 600

gaaaagggcc cgggc 615

<210> 5

<211> 232

<212> PRT

<213>unknown

<400> 5

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Trp Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser

100 105 110

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Glu Ile Val

115 120 125

Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala

130 135 140

Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp

145 150 155 160

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala

165 170 175

Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Phe

180 185 190

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe

195 200 205

Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg Thr Phe Gly

210 215 220

Gln Gly Thr Lys Val Glu Ile Lys

225 230

<210> 6

<211> 696

<212> DNA

<213>artificial sequence

<400> 6

caggtgcagc tggtggagtc cggcggcggc gtggtgcagc ctggccggtc cctgcggctg 60

gactgcaagg cctccggcat caccttctcc aactccggca tgcactgggt gcggcaggcc 120

cctggcaagg gcctggagtg ggtggcctgg atctggtacg acggctccaa gcggtactac 180

gccgactccg tgaagggccg gttcaccatc tcccgggaca actccaagaa caccctgttc 240

ctgcagatga actccctgcg ggccgaggac accgccgtgt actactgcgc caccaacgac 300

gactactggg gccagggcac cctggtgacc gtgtcctccg gcgggtccgg cgggtccggc 360

gggtccggcg ggtccgagat cgtgctgacc cagtcccctg ccaccctgtc cctgtcccct 420

ggcgagcggg ccaccctgtc ctgccgggcc tcccagtccg tgtcctccta cctggcctgg 480

taccagcaga agcctggcca ggcccctcgg ctgctgatct acgacgcctc caaccgggcc 540

accggcatcc ctgcccggtt ctccggctcc ggcttcggca ccgacttcac cctgaccatc 600

tcctccctgg agcctgagga cttcgccgtg tactactgcc agcagtcctc caactggcct 660

cggaccttcg gccagggcac caaggtggag atcaag 696

<210> 7

<211> 232

<212> PRT

<213>unknown

<400> 7

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser

20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Trp Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Ser Asn Glu Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser

100 105 110

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Glu Ile Val

115 120 125

Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala

130 135 140

Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp

145 150 155 160

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala

165 170 175

Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Phe

180 185 190

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe

195 200 205

Ala Val Tyr Tyr Cys Gln Gln Ser Thr Asn Phe Pro Arg Thr Phe Gly

210 215 220

Gln Gly Thr Lys Val Glu Ile Lys

225 230

<210> 8

<211> 696

<212> DNA

<213>artificial sequence

<400> 8

caggtgcagc tggtggagtc cggcggcggc gtggtgcagc ctggccggtc cctgcggctg 60

gactgcaagg cctccggcat caccttctcc aactccggca tgcactgggt gcggcaggcc 120

cctggcaagg gcctggagtg ggtggcctgg atctggtacg acggctccaa gcggtactac 180

gccgactccg tgaagggccg gttcaccatc tcccgggaca actccaagaa caccctgttc 240

ctgcagatga actccctgcg ggccgaggac accgccgtgt actactgcgc ctccaacgag 300

gacttctggg gccagggcac cctggtgacc gtgtcctccg gcgggtccgg cgggtccggc 360

gggtccggcg ggtccgagat cgtgctgacc cagtcccctg ccaccctgtc cctgtcccct 420

ggcgagcggg ccaccctgtc ctgccgggcc tcccagtccg tgtcctccta cctggcctgg 480

taccagcaga agcctggcca ggcccctcgg ctgctgatct acgacgcctc caaccgggcc 540

accggcatcc ctgcccggtt ctccggctcc ggcttcggca ccgacttcac cctgaccatc 600

tcctccctgg agcctgagga cttcgccgtg tactactgcc agcagtccac caacttccct 660

cggaccttcg gccagggcac caaggtggag atcaag 696

<210> 9

<211> 227

<212> PRT

<213>unknown

<400> 9

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys

225

<210> 10

<211> 681

<212> DNA

<213>artificial sequence

<400> 10

gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc 60

ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 120

tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 180

ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac 240

cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag 300

tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 360

gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag 420

aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 480

tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 540

gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg 600

aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 660

ctctccctgt ctccgggtaa a 681

<210> 11

<211> 227

<212> PRT

<213>unknown

<400> 11

Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser

130 135 140

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys

225

<210> 12

<211> 684

<212> DNA

<213>artificial sequence

<400> 12

gagcgcaaat gttgtgtcga gtgcccaccg tgcccagcac cacctgtggc aggaccgtca 60

gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc 120

acgtgcgtgg tggtggacgt gagccacgaa gaccccgagg tccagttcaa ctggtacgtg 180

gacggcgtgg aggtgcataa tgccaagaca aagccacggg aggagcagtt caacagcacg 240

ttccgtgtgg tcagcgtcct caccgttgtg caccaggact ggctgaacgg caaggagtac 300

aagtgcaagg tctccaacaa aggcctccca gcccccatcg agaaaaccat ctccaaaacc 360

aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga ggagatgacc 420

aagaaccagg tcagcctgac ctgcctggtc aaaggcttct accccagcga catcgccgtg 480

gagtgggaga gcaatgggca gccggagaac aactacaaga ccacacctcc catgctggac 540

tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag 600

gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag 660

agcctctccc tgtctccggg taaa 684

<210> 13

<211> 264

<212> PRT

<213>unknown

<400> 13

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys

1 5 10 15

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro

20 25 30

Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Ala

35 40 45

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro

50 55 60

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val

65 70 75 80

Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Lys Trp Tyr Val

85 90 95

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln

100 105 110

Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His Gln

115 120 125

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala

130 135 140

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro

145 150 155 160

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr

165 170 175

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser

180 185 190

Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gln Pro Glu Asn Asn Tyr

195 200 205

Asn Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr

210 215 220

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile Phe

225 230 235 240

Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys

245 250 255

Ser Leu Ser Leu Ser Pro Gly Lys

260

<210> 14

<211> 792

<212> DNA

<213>artificial sequence

<400> 14

gagctcaaaa ccccacttgg tgacacaact cacacatgcc cacggtgccc agagcccaaa 60

tcttgtgaca cacctccccc gtgcccacgg tgcccagagc ccaaatcttg tgacacacct 120

cccccatgcc cacggtgccc agcacctgaa ctcctgggag gaccgtcagt cttcctcttc 180

cccccaaaac ccaaggatac ccttatgatt tcccggaccc ctgaggtcac gtgcgtggtg 240

gtggacgtga gccacgaaga ccccgaggtc cagttcaagt ggtacgtgga cggcgtggag 300

gtgcataatg ccaagacaaa gccgcgggag gagcagttca acagcacgtt ccgtgtggtc 360

agcgtcctca ccgtcctgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtc 420

tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaaaccaa aggacagccc 480

cgagaaccac aggtgtacac cctgccccca tcccgggagg agatgaccaa gaaccaggtc 540

agcctgacct gcctggtcaa aggcttctac cccagcgaca tcgccgtgga gtgggagagc 600

agcgggcagc cggagaacaa ctacaacacc acgcctccca tgctggactc cgacggctcc 660

ttcttcctct acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacatcttc 720

tcatgctccg tgatgcatga ggctctgcac aaccgcttca cgcagaagag cctctccctg 780

tctccgggta aa 792

<210> 15

<211> 229

<212> PRT

<213>unknown

<400> 15

Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu

1 5 10 15

Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp

20 25 30

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp

35 40 45

Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly

50 55 60

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn

65 70 75 80

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp

85 90 95

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro

100 105 110

Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu

115 120 125

Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn

130 135 140

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile

145 150 155 160

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr

165 170 175

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg

180 185 190

Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys

195 200 205

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu

210 215 220

Ser Leu Ser Leu Gly

225

<210> 16

<211> 687

<212> DNA

<213>artificial sequence

<400> 16

gctgagtcca agtatggccc tccctgccct ccttgccctg ctcctgaggc tgctggaggc 60

cctagcgtgt tcctgttccc ccctaagcct aaggacaccc tgatgatttc ccggaccccc 120

gaggtgacct gtgtggtggt ggatgtgtcc caggaggacc ctgaagtgca gttcaactgg 180

tacgtggacg gcgtggaggt gcacaacgcc aagaccaagc cccgggaaga gcagttcaac 240

agcacctaca gggtggtgag cgtgctgacc gtgctgcacc aggactggct gaacggcaaa 300

gagtacaagt gcaaggtgag caataagggc ctgccctcct ccatcgagaa gaccatttcc 360

aaggccaagg gccagcccag ggaaccccag gtgtacaccc tccctcccag ccaggaggag 420

atgaccaaga accaggtgtc cctgacctgc ctggtgaaag gcttctaccc ctccgacatt 480

gccgtcgagt gggaaagcaa cggccagccc gagaacaatt acaagaccac accccccgtg 540

ctggacagcg atggcagctt tttcctgtac tccaggctga ccgtcgacaa gtccaggtgg 600

caggagggca acgtcttctc ctgctccgtg atgcatgagg ccctgcacaa ccactacacc 660

cagaagtccc tgtccctgag cctgggc 687

<210> 17

<211> 684

<212> PRT

<213>unknown

<400> 17

Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His

1 5 10 15

Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro

20 25 30

Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro

35 40 45

Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser

50 55 60

Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val

65 70 75 80

Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn

85 90 95

Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser

100 105 110

Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn

115 120 125

Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His

130 135 140

Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met

145 150 155 160

Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp

165 170 175

Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys

180 185 190

Asn Ser Thr Phe Val Arg Val His Glu Lys Gly Gly Ser Gly Gly Ser

195 200 205

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

210 215 220

Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser

225 230 235 240

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

245 250 255

Ala Trp Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val

260 265 270

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe

275 280 285

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

290 295 300

Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser

305 310 315 320

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Glu Ile Val

325 330 335

Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala

340 345 350

Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp

355 360 365

Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala

370 375 380

Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Phe

385 390 395 400

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe

405 410 415

Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg Thr Phe Gly

420 425 430

Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly

435 440 445

Gly Ser Gly Gly Gly Gly Ser Ala Glu Ser Lys Tyr Gly Pro Pro Cys

450 455 460

Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu

465 470 475 480

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu

485 490 495

Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln

500 505 510

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

515 520 525

Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu

530 535 540

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys

545 550 555 560

Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys

565 570 575

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser

580 585 590

Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys

595 600 605

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln

610 615 620

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly

625 630 635 640

Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln

645 650 655

Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn

660 665 670

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly

675 680

<210> 18

<211> 2159

<212> DNA

<213>artificial sequence

<400> 18

agatctccta gggccaccat ggtcagctac tgggacaccg gggtcctgct gtgcgcgctg 60

ctcagctgtc tgcttctcac aggatctagt tccggaggta gacctttcgt agagatgtac 120

agtgaaatcc ccgaaattat acacatgact gaaggaaggg agctcgtcat tccctgccgg 180

gttacgtcac ctaacatcac tgttacttta aaaaagtttc cacttgacac tttgatccct 240

gatggaaaac gcataatctg ggacagtaga aagggcttca tcatatcaaa tgcaacgtac 300

aaagaaatag ggcttctgac ctgtgaagca acagtcaatg ggcatttgta taagacaaac 360

tatctcacac atcgacaaac caatacaatc atagatgtgg ttctgagtcc gtctcatgga 420

attgaactat ctgttggaga aaagcttgtc ttaaattgta cagcaagaac tgaactaaat 480

gtggggattg acttcaactg ggaataccct tcttcgaagc atcagcataa gaaacttgta 540

aaccgagacc taaaaaccca gtctgggagt gagatgaaga aatttttgag caccttaact 600

atagatggtg taacccggag tgaccaagga ttgtacacct gtgcagcatc cagtgggctg 660

atgaccaaga agaacagcac atttgtcagg gtccatgaaa agggcgggtc cggcgggtcc 720

caggtgcagc tggtggagtc cggcggcggc gtggtgcagc ctggccggtc cctgcggctg 780

gactgcaagg cctccggcat caccttctcc aactccggca tgcactgggt gcggcaggcc 840

cctggcaagg gcctggagtg ggtggcctgg atctggtacg acggctccaa gcggtactac 900

gccgactccg tgaagggccg gttcaccatc tcccgggaca actccaagaa caccctgttc 960

ctgcagatga actccctgcg ggccgaggac accgccgtgt actactgcgc caccaacgac 1020

gactactggg gccagggcac cctggtgacc gtgtcctccg gcgggtccgg cgggtccggc 1080

gggtccggcg ggtccgagat cgtgctgacc cagtcccctg ccaccctgtc cctgtcccct 1140

ggcgagcggg ccaccctgtc ctgccgggcc tcccagtccg tgtcctccta cctggcctgg 1200

taccagcaga agcctggcca ggcccctcgg ctgctgatct acgacgcctc caaccgggcc 1260

accggcatcc ctgcccggtt ctccggctcc ggcttcggca ccgacttcac cctgaccatc 1320

tcctccctgg agcctgagga cttcgccgtg tactactgcc agcagtcctc caactggcct 1380

cggaccttcg gccagggcac caaggtggag atcaagggcg gcggaggctc cggcggaggc 1440

ggctccggcg gcggcggctc cgctgagtcc aagtatggcc ctccctgccc tccttgccct 1500

gctcctgagg ctgctggagg ccctagcgtg ttcctgttcc cccctaagcc taaggacacc 1560

ctgatgattt cccggacccc cgaggtgacc tgtgtggtgg tggatgtgtc ccaggaggac 1620

cctgaagtgc agttcaactg gtacgtggac ggcgtggagg tgcacaacgc caagaccaag 1680

ccccgggaag agcagttcaa cagcacctac agggtggtga gcgtgctgac cgtgctgcac 1740

caggactggc tgaacggcaa agagtacaag tgcaaggtga gcaataaggg cctgccctcc 1800

tccatcgaga agaccatttc caaggccaag ggccagccca gggaacccca ggtgtacacc 1860

ctccctccca gccaggagga gatgaccaag aaccaggtgt ccctgacctg cctggtgaaa 1920

ggcttctacc cctccgacat tgccgtcgag tgggaaagca acggccagcc cgagaacaat 1980

tacaagacca caccccccgt gctggacagc gatggcagct ttttcctgta ctccaggctg 2040

accgtcgaca agtccaggtg gcaggagggc aacgtcttct cctgctccgt gatgcatgag 2100

gccctgcaca accactacac ccagaagtcc ctgtccctga gcctgggctg attaattaa 2159

Claims (5)

Translated fromChinese

1. 一种新型融合蛋白，其特征在于，其由核苷酸序列SEQ ID NO：18所编码。1. a novel fusion protein, is characterized in that, it is encoded by nucleotide sequence SEQ ID NO:18.2.一种制备新型融合蛋白的方法，其特征在于，将权利要求1所述新型融合蛋白的编码核苷酸序列插入表达载体中，并将此表达载体引入相应的表达系统进而进行融合蛋白的表达。2. a method for preparing a novel fusion protein is characterized in that, inserting the nucleotide sequence encoding the novel fusion protein of claim 1 into an expression vector, and introducing this expression vector into a corresponding expression system and then carrying out the fusion of the fusion protein. Express.3.一种药物组合物，其特征在于，由权利要求1所述的新型融合蛋白与药学上可接受的载体或赋形剂组成。3. A pharmaceutical composition, characterized in that, it is composed of the novel fusion protein of claim 1 and a pharmaceutically acceptable carrier or excipient.4.根据权利要求3所述的一种药物组合物，其特征在于，所述药物组合物的制剂形式为注射剂。4. A kind of pharmaceutical composition according to claim 3, is characterized in that, the preparation form of described pharmaceutical composition is injection.5.一种新型融合蛋白的用途，其特征在于，所述权利要求1所述的新型融合蛋白用于肿瘤治疗药物的制备；所述肿瘤为黑色素瘤、肺癌、肝癌、淋巴瘤、结肠癌、大肠癌、乳腺癌、卵巢癌、宫颈癌、胃癌、胆管癌、胆囊癌、食管癌、肾癌、神经胶质瘤、胰腺癌和前列腺癌中的一种或多种。5. Use of a novel fusion protein, characterized in that the novel fusion protein of claim 1 is used for the preparation of a tumor therapeutic drug; the tumor is melanoma, lung cancer, liver cancer, lymphoma, colon cancer, One or more of colorectal cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, bile duct cancer, gallbladder cancer, esophageal cancer, kidney cancer, glioma, pancreatic cancer and prostate cancer.